CRESCENT BIOPHARMA INC (CBIO) Forecast, Price Target & Analyst Ratings

Q: What do analysts expect the price target to be for CRESCENT BIOPHARMA INC (CBIO)?

15 analysts have analysed CBIO and the average price target is 28.9 USD. This implies a price increase of 38.01% is expected in the next year compared to the current price of 20.94.

NASDAQ:CBIO • KYG2545C1042

20.94 USD

-3.02 (-12.6%)

Last: Apr 29, 2026, 08:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRESCENT BIOPHARMA INC (CBIO).

Consensus Price Target

Price Target

$28.90

+ 38.01% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.97
Revenue Estimate: 364.283K

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

86.67%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$28.90

Upside

+ 38.01%

From current price of $20.94 to mean target of $28.90, Based on 15 analyst forecasts

Low

$22.22

Median

$28.56

High

$36.75

Price Target Revisions

1 Month

-3.41%

3 Months

6.92%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for CBIO. The average price target is 28.9 USD. This implies a price increase of 38.01% is expected in the next year compared to the current price of 20.94.

The average price target has been revised upward by 6.92% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

86.67%

CBIO was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about CBIO.

In the previous month the buy percentage consensus was at a similar level.

CBIO was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-02	HC Wainwright & Co.	Maintains	Buy -> Buy
2026-01-21	Guggenheim	Initiate	Buy
2025-08-27	HC Wainwright & Co.	Reiterate	Buy -> Buy
2025-08-25	Jefferies	Initiate	Buy
2025-08-11	HC Wainwright & Co.	Initiate	Buy
2025-07-14	Wedbush	Initiate	Outperform
2025-06-25	Stifel	Initiate	Buy
2025-06-18	LifeSci Capital	Initiate	Outperform
2021-11-15	Raymond James	Downgrade	Outperform -> Market Perform
2021-08-06	Raymond James	Maintains	Outperform
2021-04-29	Raymond James	Maintains	Outperform
2021-02-10	Piper Sandler	Initiate	Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.97
Revenue Estimate: 364.283K
Revenue Q2Q: N/A
EPS Q2Q: 75.86%
Number of Analysts: 9

Next Earnings Revisions

Revenue (1 Month)

0.00%

Revenue (3 Months)

N/A

EPS (1 Month)

0.00%

EPS (3 Months)

65.05%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	10K -87.50%	-100.00%	10.844M	1.457M -86.56%	5.525M 279.20%	6.8M 23.08%	34.578M 408.50%	104.99M 203.63%	290.33M 176.53%	627.86M 116.26%	1.226B 95.27%
EBITDA YoY % growth	-39.122M 17.10%	-32.474M 16.99%	-145.342M -347.57%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-39.275M 17.14%	-32.509M 17.23%	-145.426M -347.34%	-120.743M 16.97%	-154.424M -27.89%	-193.499M -25.30%	-238.154M -23.08%	-239.01M -0.36%	-82.2M 65.61%	140.82M 271.31%	445.48M 216.35%
Operating Margin	-392,753.00%	N/A	-1,341.07%	-8,287.11%	-2,795.00%	-2,845.58%	-688.74%	-227.65%	-28.31%	22.43%	36.34%
EPS YoY % growth	-58.00 34.09%	N/A 98.93%	-10.74 -1,633.24%	-3.97 63.02%	-3.88 2.27%	-4.41 -13.66%	-4.62 -4.66%	-4.03 12.81%	-3.68 8.53%	0.61 116.48%	10.08 1,560.50%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27
EPS Q2Q % growth	-0.97 75.86%	-1.01 79.56%	-0.99 22.24%	-1.04 -91.70%	-1.24 -28.89%	-1.28 -26.50%	-1.29 -30.15%	-1.02 1.46%
Revenue Q2Q % growth	364.283K	364.283K	364.283K	364.283K -96.64%	-100.00%	-100.00%	-100.00%	-100.00%
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-27.976M -1,066.20%	-29.491M -40.23%	-30.866M -19.24%	-32.425M 61.53%	-40.698M -45.47%	-41.616M -41.11%	-42.228M -36.81%	-43.146M -33.06%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

16.70%

EPS Next 5 Year

10.20%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CRESCENT BIOPHARMA INC / CBIO Forecast FAQ

What do analysts expect the price target to be for CRESCENT BIOPHARMA INC (CBIO)?

15 analysts have analysed CBIO and the average price target is 28.9 USD. This implies a price increase of 38.01% is expected in the next year compared to the current price of 20.94.

What are the consensus estimates for CBIO stock next earnings?

The consensus EPS estimate for the next earnings of CRESCENT BIOPHARMA INC (CBIO) is -0.97 USD and the consensus revenue estimate is 364.28K USD.

Analyst forecast overview

Forecast Snapshot